EARS - Auris Medical launches second part of mid-stage study with AM-125 in vertigo

Nano-cap Auris Medical (EARS) soars 75% in premarket, on initiation of Part B of its Phase 2 TRAVERS trial evaluating AM-125 (intranasal betahistine) in acute vertigo following neurosurgery.In Part B of the TRAVERS trial, the Company will enroll 72 patients. Improvement in the “Standing on Foam” test from baseline to Day 14 will be the primary efficacy endpoint; the improvement in the “Tandem Romberg” test to Day 42 will be the key secondary efficacy endpoint. The two tests measure how long patients are able to maintain balance on a foam mat or with the two feet aligned one after the other, respectively, while they have their eyes closed.Part A of the trial, demonstrated good safety and tolerability of AM-125 and observed a compelling dose response effect with active treated patients, showing up to 1.9 to 2.4 times better performance in key balance tests.Enrollment for Part B is expected to conclude by the

For further details see:

Auris Medical launches second part of mid-stage study with AM-125 in vertigo